Physician profile
Srinivasan Ramanuja
NPI 1720184849
$18,071.63
in general payments reported to CMS, 2019-2025
32 companies · $15K in 2025
The $15K reported for 2025 was more than what 91% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $377 · 2020: $169 · 2021: $224 · 2022: $384 · 2023: $1,305 · 2024: $261 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Consulting Fee: $1,215 · Travel and Lodging: $1,075 · Food and Beverage: $953 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,650.00 |
| Consulting Fee | $1,215.00 |
| Travel and Lodging | $1,075.40 |
| Food and Beverage | $952.55 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $15,298.57 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Genentech USA, INC. | $1,262.11 | 2023-2024 | Xolair |
| Amgen INC. | $177.30 | 2021-2025 | Tezspire, Actimmune |
| Kaleo, INC. | $118.77 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $98.98 | 2020-2024 | Dupixent |
| Alk-Abello, INC | $95.67 | 2019 | |
| Pharming Healthcare, INC. | $85.54 | 2020-2025 | Ruconest |
| Teva Pharmaceuticals USA, INC. | $83.51 | 2021-2022 | |
| Csl Behring | $67.71 | 2019-2022 | |
| Genzyme Corporation | $64.09 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.91 | 2019-2022 | |
| Biocryst US Sales Co., LLC | $59.58 | 2021-2023 | Orladeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $58.62 | 2020-2024 | Eohilia |
| Grifols USA, LLC | $55.55 | 2020-2025 | Xembify |
| Glaxosmithkline, LLC. | $50.58 | 2020-2024 | Trelegy Ellipta |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $49.36 | 2025 | Neffy |
| Novartis Pharmaceuticals Corporation | $46.16 | 2019-2025 | |
| Optinose US, INC. | $45.93 | 2024-2025 | |
| Ionis Pharmaceuticals, INC. | $40.15 | 2025 | Dawnzera |
| Pfizer INC. | $37.41 | 2023-2024 | |
| Insmed, INC. | $33.34 | 2024-2025 | Arikayce |
| Philips North America LLC | $29.71 | 2020-2021 | |
| Cycle Pharmaceuticals INC | $24.10 | 2025 | Sajazir |
| Uswm, LLC | $23.70 | 2021 | |
| Octapharma USA, INC. | $23.51 | 2019-2021 | |
| Axonics, INC. | $21.41 | 2023 | Axonics |
| Shire North American Group INC | $16.90 | 2019 | |
| Tersera Therapeutics LLC | $16.53 | 2025 | Quzyttir |
| Incyte Corporation | $13.86 | 2025 | Opzelura |
| Phathom Pharmaceuticals, INC. | $13.07 | 2024 | Voquezna |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Srinivasan Ramanuja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.